The Annals the journal of Pharmacy Technology
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 35, No. 3, pp. 300-302. DOI 10.1345/aph.10178
© 2001 Harvey Whitney Books Company.
This Article
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Roefaro, J
Right arrow Articles by Mukherjee, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Roefaro, J
Right arrow Articles by Mukherjee, S.

Research Articles

Olanzapine-lnduced hyperglycemic nonketonic coma

J Roefaro and SM Mukherjee

OBJECTIVE: To report a case of olanzapine-induced hyperglycemia leading to a hyperosmolar, hyperglycemic, nonketonic coma. CASE SUMMARY: A 51-year-old, 85.5-kg (ideal body weight 79.9 kg), white man presented to a Veterans Affairs hospital with a serum glucose concentration of 1596 mg/dL. Soon thereafter, he went into a hyperosmolar, hyperglycemic, nonketonic coma. Olanzapine therapy had been instituted less than six months prior to this event; approximately two months before this event, his blood glucose was 108 mg/dL. Eight days after stopping olanzapine, the glucose concentration returned to normal, and the patient no longer required insulin nor any other glucose-lowering agents. DISCUSSION: The insulin resistance caused by olanzapine is normally attributed to the weight gain associated with the drug. In this patient, it appears that olanzapine caused hyperglycemia by a mechanism other than weight gain. CONCLUSIONS: This case report and others from the literature suggest that olanzapine therapy may induce hyperglycemia in some patients.


This article has been cited by other articles:


Home page
 The Annals of PharmacotherapyHome page
I. Kohen, M. Gampel, L. Reddy, and P. Manu
Rapidly Developing Hyperglycemia During Treatment with Olanzapine
Ann. Pharmacother., April 1, 2008; 42(4): 588 - 591.
[Abstract] [Full Text] [PDF]

Home page
 Am J EpidemiolHome page
B. L. Lambert, F. E. Cunningham, D. R. Miller, G. W. Dalack, and K. Hur
Diabetes Risk Associated with Use of Olanzapine, Quetiapine, and Risperidone in Veterans Health Administration Patients with Schizophrenia
Am. J. Epidemiol., October 1, 2006; 164(7): 672 - 681.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
P. S. Chen, Y. K. Yang, T. L. Yeh, Y. C. Lo, and Y. T. Wang
Nonketotic hyperosmolar syndrome from olanzapine, lithium, and valproic acid cotreatment
Ann. Pharmacother., June 1, 2003; 37(6): 919 - 920.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
M. E.J. Lean and F.-G. Pajonk
Patients on Atypical Antipsychotic Drugs: Another high-risk group for type 2 diabetes
Diabetes Care, May 1, 2003; 26(5): 1597 - 1605.
[Abstract] [Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 2001 by Harvey Whitney Books Company.